Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Med 2021 | SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS

Jo Brewer, PhD, Adaptimmune, Philadelphia, PA, introduces the ongoing Phase II SPEARHEAD-1 trial (NCT04044768), assessing the efficacy and safety of ADP-A2M4 in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The ADP-A2M4 SPEAR T-cell therapy targets the MAGE- A4 antigen presented by HLA-A2+ patients. This interview took place during the Cell & Gene Meeting on the Mediterranean 2021 virtual conference.